Ind-Swift Laboratories Beheer
Beheer criteriumcontroles 2/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Navrattan Munjal
Algemeen directeur
₹30.3m
Totale compensatie
| Percentage CEO-salaris | 99.9% |
| Dienstverband CEO | 29.6yrs |
| Eigendom CEO | 1.6% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 5.5yrs |
Recente managementupdates
Recent updates
Ind-Swift Laboratories Limited's (NSE:INDSWFTLAB) Revenues Are Not Doing Enough For Some Investors
Oct 20
Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Stock Rockets 29% But Many Are Still Ignoring The Company
Jul 02Shareholders In Ind-Swift Laboratories (NSE:INDSWFTLAB) Should Look Beyond Earnings For The Full Story
May 21Ind-Swift Laboratories Limited (NSE:INDSWFTLAB) Surges 26% Yet Its Low P/E Is No Reason For Excitement
Apr 13Here's Why Ind-Swift Laboratories (NSE:INDSWFTLAB) Can Manage Its Debt Responsibly
Dec 28These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Reasonably Well
Jul 22Ind-Swift Laboratories (NSE:INDSWFTLAB) Has A Somewhat Strained Balance Sheet
Jul 12Did Business Growth Power Ind-Swift Laboratories' (NSE:INDSWFTLAB) Share Price Gain of 231%?
Feb 17We're Not So Sure You Should Rely on Ind-Swift Laboratories's (NSE:INDSWFTLAB) Statutory Earnings
Dec 30These 4 Measures Indicate That Ind-Swift Laboratories (NSE:INDSWFTLAB) Is Using Debt Extensively
Nov 11Is Ind-Swift Laboratories (NSE:INDSWFTLAB) A Risky Investment?
Jun 27Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | ₹4b |
| Mar 31 2024 | ₹30m | ₹30m | ₹4b |
| Dec 31 2023 | n/a | n/a | ₹432m |
| Sep 30 2023 | n/a | n/a | ₹513m |
| Jun 30 2023 | n/a | n/a | ₹450m |
| Mar 31 2023 | ₹36m | ₹36m | ₹476m |
| Dec 31 2022 | n/a | n/a | ₹113m |
| Sep 30 2022 | n/a | n/a | -₹2m |
| Jun 30 2022 | n/a | n/a | -₹11m |
| Mar 31 2022 | ₹36m | ₹36m | -₹21m |
| Dec 31 2021 | n/a | n/a | ₹301m |
| Sep 30 2021 | n/a | n/a | ₹256m |
| Jun 30 2021 | n/a | n/a | ₹111m |
| Mar 31 2021 | ₹33m | ₹33m | -₹31m |
| Dec 31 2020 | n/a | n/a | ₹277m |
| Sep 30 2020 | n/a | n/a | ₹77m |
| Jun 30 2020 | n/a | n/a | -₹111m |
| Mar 31 2020 | ₹30m | ₹30m | -₹212m |
| Dec 31 2019 | n/a | n/a | -₹734m |
| Sep 30 2019 | n/a | n/a | -₹211m |
| Jun 30 2019 | n/a | n/a | -₹35m |
| Mar 31 2019 | ₹18m | ₹18m | ₹289m |
| Mar 31 2018 | ₹18m | ₹18m | ₹220m |
Compensatie versus markt: De totale vergoeding ($USD 360.42K ) Navrattan } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 42.81K ).
Compensatie versus inkomsten: De vergoeding van Navrattan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Navrattan Munjal (72 yo)
29.6yrs
Tenure
₹30,308,000
Compensatie
Mr. Navrattan R. Munjal has been a Managing Director of Ind-swift Laboratories Ltd. since March 29, 2001 and serves as its Chairman. He served as President of Indian Drug Manufacturers’ Association until J...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman & MD | 29.6yrs | ₹30.31m | 1.56% ₹ 110.4m | |
| Joint MD & Whole Time Director | 21.3yrs | ₹37.88m | 0.69% ₹ 48.8m | |
| Executive Director | 14.7yrs | ₹15.16m | 0.77% ₹ 54.9m | |
| President of Operations & Special Assignments and Executive Director | 4.8yrs | ₹17.92m | 0.011% ₹ 811.2k | |
| Non-Executive Independent Director | 12.2yrs | ₹186.75k | geen gegevens | |
| Non-Executive Independent Director | 4.8yrs | ₹123.75k | geen gegevens | |
| Non-Executive Independent Woman Director | 5.5yrs | ₹85.50k | geen gegevens | |
| Non-Executive Independent Director | 3.4yrs | ₹148.50k | geen gegevens | |
| Independent Director | less than a year | geen gegevens | geen gegevens |
5.5yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van INDSWFTLAB wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).